- Home
- RVPH vs CRDL Comparison
RVPH vs CRDL Comparison
Compare RVPH & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- CRDL
- Stock Information
- Founded
- RVPH 2006
- CRDL 2017
- Country
- RVPH United States
- CRDL Canada
- Employees
- RVPH N/A
- CRDL N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVPH Health Care
- CRDL Health Care
- Exchange
- RVPH Nasdaq
- CRDL Nasdaq
- Market Cap
- RVPH 88.0M
- CRDL 102.0M
- IPO Year
- RVPH N/A
- CRDL N/A
- Fundamental
- Price
- RVPH $1.04
- CRDL $1.15
- Analyst Decision
- RVPH Strong Buy
- CRDL Strong Buy
- Analyst Count
- RVPH 5
- CRDL 3
- Target Price
- RVPH $11.40
- CRDL $9.00
- AVG Volume (30 Days)
- RVPH 1.1M
- CRDL 283.5K
- Earning Date
- RVPH 05-13-2025
- CRDL 03-31-2025
- Dividend Yield
- RVPH N/A
- CRDL N/A
- EPS Growth
- RVPH N/A
- CRDL N/A
- EPS
- RVPH N/A
- CRDL N/A
- Revenue
- RVPH N/A
- CRDL N/A
- Revenue This Year
- RVPH N/A
- CRDL N/A
- Revenue Next Year
- RVPH N/A
- CRDL N/A
- P/E Ratio
- RVPH N/A
- CRDL N/A
- Revenue Growth
- RVPH N/A
- CRDL N/A
- 52 Week Low
- RVPH $0.60
- CRDL $1.02
- 52 Week High
- RVPH $4.28
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- RVPH 25.55
- CRDL 46.66
- Support Level
- RVPH $1.12
- CRDL $1.03
- Resistance Level
- RVPH $1.23
- CRDL $1.20
- Average True Range (ATR)
- RVPH 0.13
- CRDL 0.10
- MACD
- RVPH -0.03
- CRDL 0.00
- Stochastic Oscillator
- RVPH 0.00
- CRDL 55.32
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.